Evidence map›Paper›PMID 36064365›Full record

ArticleJournal of nanobiotechnology2022

Hydrogel-metal-organic-framework hybrids mediated efficient oral delivery of siRNA for the treatment of ulcerative colitis.

Meng Gao, Chen Yang, Chenghu Wu, Yue Chen, Hongqin Zhuang, Jilong Wang, Zhiting Cao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 59 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Metal-organic frameworks in oral drug delivery.Asian journal of pharmaceutical sciences · 2024
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Meng GaoDepartment of Gastroenterology, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, 230011, China.
Chen YangSchool of Biopharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Chenghu WuZhejiang Engineering Research Center for Tissue Repair Materials, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325000, Zhejiang, China.
Yue ChenSchool of Clinical Medicine, Anhui Medical University, Hefei, 230000, China.
Hongqin ZhuangSchool of Life Sciences, Nanjing University, Nanjing, 210023, China. hqzhuang@nju.edu.cn.
Jilong WangZhejiang Engineering Research Center for Tissue Repair Materials, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325000, Zhejiang, China. wangjilong@ucas.ac.cn.
Zhiting CaoSchool of Biopharmacy, China Pharmaceutical University, Nanjing, 210009, China. caozt@cpu.edu.cn.
Anhui Medical University · CNChina Pharmaceutical University · CNUniversity of Chinese Academy of Sciences · CNNanjing University · CN

Funding

Basic Public Welfare Research Program of Zhejiang Province LGJ22C100001the Natural Science Foundation of Jiangsu Province BK20211221Wenzhou Institute, University of Chinese Academy of Sciences WIUCASQD2020014Wenzhou Scientific Research Project Y2020175
6 · The paper itself

Abstract

backgroundUlcerative colitis (UC) is a major type of inflammatory bowel disease (IBD), which could induce bloody stool, diarrhea, colon atrophy and eventually lead to colorectal cancer. The conventional daily oral administration of drugs only relieve the inflammatory response of colon in the short term, Biological agents such as antibody drugs has proven its efficiency in inhibiting colitis, while the low drug bioavailability means that large doses of antibodies are required, ultimately causing systemic toxicity. Small interfering RNA (siRNA) has significant advantages over antibody drugs in terms of safety and efficacy, and it have been widely applied as potential candidates for a variety of inflammation-related diseases. However, oral delivery of siRNA fails to overcome the degradation of the gastrointestinal environment to produce a significant therapeutic effect in ulcerative colitis. Herein, we design the hybrid delivery system that the siRNA loaded MOF encapsulated in the sodium alginate particles to overcome the barriers in the oral process.

resultsThe hybrid delivery system (SA@MOF-siRNA

conclusionWe confirmed that the formulation of hydrogel-metal-organic framework hybrids could improve the protection of incorporated payload in the gastric and early small intestine, enhancing the delivery of MOF-siRNA to colon.

Indexed as

ColitisColitis, UlcerativeMetal-Organic FrameworksAnimalsDiarrheaHydrogelsMiceRNA, Small InterferingTumor Necrosis Factor-alphaHydrogelsMetal-Organic FrameworksRNA, Small InterferingTumor Necrosis Factor-alphaDelivery systemGastric-intestinal environmentHydrogel–metal-organic framework hybridsSodium alginateUlcerative colitis

Identifiers

PMID36064365
PMCPMC9446571
OpenAlexW4294647454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.